TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31461392

Group type: EXPERIMENTAL
Intervention: Scotchbond Universal (SBU)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Futurabond U (FBU)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Prime&Bond Elect (PBE)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etch-and-rinse (ER) strategy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Self-etch (SE) strategy
Number of subjects: 60
Study: 28974406

Group type: EXPERIMENTAL
Intervention: CCH 0.58 mg plus vacuum therapy alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CCH 0.58 mg plus vacuum therapy with penile modeling
Number of subjects: 30
Study: 26118143

Group type: EXPERIMENTAL
Intervention: Community-based intervention using the ISHIB IMPACT cardiovascular risk reduction toolkit
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 54
Study: 23745440

Group type: EXPERIMENTAL
Intervention: Medical or surgical closure of ductus arteriosus (DA)
Number of subjects: 32

Group type: COMPARATOR
Intervention: No intervention (Group B)
Number of subjects: 32
Study: 22232999

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 512

Group type: COMPARATOR
Intervention: Midazolam plus pethidine
Number of subjects: 512
Study: 19833276

Group type: EXPERIMENTAL
Intervention: Group L (0.1 mL/kg of preservative‐free 1% lidocaine pretreatment, slow rocuronium injection)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Group R (0.1 mL/kg of 0.9% NaCl pretreatment, rapid rocuronium injection)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Group C (0.1 mL/kg of 0.9% NaCl pretreatment, slow rocuronium injection)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Group L vs Group R
Number of subjects: 150
Study: 17076848

Group type: EXPERIMENTAL
Intervention: Patient self-assessment of bleeding symptoms
Number of subjects: 35

Group type: COMPARATOR
Intervention: Study assessor assessment of bleeding symptoms
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Patient self-assessment
Number of subjects: 35
Study: 15283899

Group type: EXPERIMENTAL
Intervention: 5 mg of finasteride daily for 7 years
Number of subjects: 0
Study: 11408340

Group type: EXPERIMENTAL
Intervention: CuZn-superoxide dismutase (CuZn-SOD) in CSF from ALS patients with D90A mutation
Number of subjects: 113

Group type: COMPARATOR
Intervention: CuZn-superoxide dismutase (CuZn-SOD) in CSF from ALS patients without CuZn-SOD mutations
Number of subjects: 113

Group type: COMPARATOR
Intervention: CuZn-superoxide dismutase (CuZn-SOD) in CSF from controls
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: CuZn-superoxide dismutase (CuZn-SOD) in CSF from D90A homozygous ALS patients
Number of subjects: 113

Group type: COMPARATOR
Intervention: Extracellular SOD in CSF
Number of subjects: 113
Study: 9252801

Group type: EXPERIMENTAL
Intervention: Tolcapone (200 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tolcapone with standard-release levodopa/benserazide formulations (50/12.5 mg, 100/25 mg, 200/50 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tolcapone with controlled-release levodopa/benserazide formulation (100/25 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8060907

Group type: EXPERIMENTAL
Intervention: Empathy-treatment
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Facts-treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 68
Study: 3565001

Group type: EXPERIMENTAL
Intervention: Sodium intake of 2 mmol/kg/day (sodium chloride)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium intake of 4 mmol/kg/day (sodium chloride and acetate)
Number of subjects: 20
Study: 29240541

Group type: EXPERIMENTAL
Intervention: Metastasis-directed therapy (MDT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 62
Study: 26763773

Group type: EXPERIMENTAL
Intervention: Etoricoxib 90 mg once daily
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 24227806

Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 32
Study: 22647783

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Azelnidipine
Number of subjects: 207
Study: 20029208

Group type: EXPERIMENTAL
Intervention: Daily placebo with pantoprazole rescue (n = 141)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Daily pantoprazole with placebo rescue (n = 62)
Number of subjects: 203
Study: 18533208

Group type: EXPERIMENTAL
Intervention: Guided-tissue regeneration (GTR) with deproteinized bovine bone and resorbable collagen membrane
Number of subjects: 55

Group type: COMPARATOR
Intervention: No GTR (control group)
Number of subjects: 55
Study: 16500168

Group type: EXPERIMENTAL
Intervention: Electric somatosensory stimulation applied to the paretic hand
Number of subjects: 9

Group type: COMPARATOR
Intervention: Electric somatosensory stimulation applied to the paretic leg
Number of subjects: 9

Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 9
Study: 15485731

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Risk-benefit acceptability curve
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Net-benefit curve
Number of subjects: 3000
Study: 11001344

Group type: EXPERIMENTAL
Intervention: Exercise (15 min of cycle ergometry at 60% V(O2max) followed by 30 min of recovery)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (remained seated with no exercise for 45 min)
Number of subjects: 6
Study: 9432219

Group type: EXPERIMENTAL
Intervention: Application of alcohol to the finger before the puncture
Number of subjects: 300

Group type: COMPARATOR
Intervention: No application of alcohol to the finger before the puncture
Number of subjects: 300

Group type: COMPARATOR
Intervention: Another intervention group (not specified)
Number of subjects: 300
Study: 8249851

Group type: EXPERIMENTAL
Intervention: ACIP protocol
Number of subjects: 44

Group type: COMPARATOR
Intervention: Bruce protocol
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ACIP and modified ACIP protocols
Number of subjects: 44

Group type: COMPARATOR
Intervention: Bruce and Cornell protocols
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: All four protocols
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: ACIP, modified ACIP, Cornell protocols
Number of subjects: 44
Study: 3920861

Group type: EXPERIMENTAL
Intervention: 200 mg Sorbinil
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 50 mg Sorbinil
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 29986690

Group type: EXPERIMENTAL
Intervention: Family Group Conferencing (FGC)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Family Group Conferencing (FGC) for families who refused FGC
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Family Group Conferencing (FGC) for families that prepared or completed FGC
Number of subjects: 69
Study: 27184219

Group type: EXPERIMENTAL
Intervention: Two-hour lecture
Number of subjects: 727

Group type: COMPARATOR
Intervention: Seven-hour series of lectures
Number of subjects: 727

Group type: COMPARATOR
Intervention: Four-hour series with a friend or close relative
Number of subjects: 727
Study: 25265777

Group type: EXPERIMENTAL
Intervention: Gabapentin generic form (GGF)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Gabapentin original form (GOF)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study: 22432521

Group type: EXPERIMENTAL
Intervention: NovoPen® 5 (NP5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HumaPen® Memoir™ (HPM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: HumaPen Luxura® (HPL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ClikSTAR® (CS)
Number of subjects: 0
Study: 20589494

Group type: EXPERIMENTAL
Intervention: Tramadol 200 mg/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Tramadol 800 mg/day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Hydromorphone (1.5, 3.0, and 6.0 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 18765698

Group type: EXPERIMENTAL
Intervention: Continuous antiretroviral therapy
Number of subjects: 5472

Group type: COMPARATOR
Intervention: Episodic antiretroviral therapy
Number of subjects: 5472
Study: 15699233

Group type: COMPARATOR
Intervention: Choline-fed mice (10 or 35 mmol choline/kg diet)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Choline-deficient mice (0 mmol choline/kg diet)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Men not choline depleted (550 mg choline/d)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Clinically choline-depleted men (low choline diet)
Number of subjects: 8
Study: 12964912

Group type: EXPERIMENTAL
Intervention: Consultation with an alternative health practitioner
Number of subjects: 41477

Group type: EXPERIMENTAL
Intervention: CAM users
Number of subjects: 41477

Group type: COMPARATOR
Intervention: CAM non-users
Number of subjects: 41477
Study: 10690245

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg) + Ivermectin (200 micrograms/kg)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg) + DEC (6 mg/kg)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Albendazole (400 mg) alone
Number of subjects: 155
Study: 8699911

Group type: EXPERIMENTAL
Intervention: Topical pilocarpine (candy-like pastille) administered in increasing dosages for 5 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical pilocarpine (candy-like pastille)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Topical pilocarpine administration
Number of subjects: 40
Study: 1873372

Group type: EXPERIMENTAL
Intervention: 100 mcg selenium daily for 5 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 6850722

Group type: EXPERIMENTAL
Intervention: guanadrel sulfate
Number of subjects: 18

Group type: COMPARATOR
Intervention: guanethidine sulfate
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: guanadrel sulfate and guanethidine sulfate
Number of subjects: 18
Study: 31815649

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg daily
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg daily
Number of subjects: 661

Group type: EXPERIMENTAL
Intervention: Upadacitinib (both doses)
Number of subjects: 661

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 661
Study: 29182407

Group type: EXPERIMENTAL
Intervention: Metformin (conventional anti-diabetic doses)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (non-treatment mixed)
Number of subjects: 65
Study: 27516139

Group type: EXPERIMENTAL
Intervention: Tegaderm™ CHG dressing
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 59
Study: 24799181

Group type: EXPERIMENTAL
Intervention: HAL photodynamic therapy (PDT) with vaginal suppository, 5 hours before illumination with 50 J/cm² red coherent light (633 nm)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo vaginal suppository
Number of subjects: 70

Group type: COMPARATOR
Intervention: Follow-up only
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: HAL photodynamic therapy (PDT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo PDT
Number of subjects: 70

Group type: COMPARATOR
Intervention: Follow-up group
Number of subjects: 70
Study: 22336284

Group type: EXPERIMENTAL
Intervention: 30 ‐ 40 newtons cricoid pressure
Number of subjects: 212

Group type: COMPARATOR
Intervention: unmeasured cricoid pressure (control)
Number of subjects: 212
Study: 19894215

Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 19039880

Group type: EXPERIMENTAL
Intervention: Household-based lifestyle intervention
Number of subjects: 57
Study: 15876944

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/d for 3 days weekly, for 3 weeks) with symptom-specific agents
Number of subjects: 352

Group type: COMPARATOR
Intervention: Symptom-specific agents alone
Number of subjects: 352
Study: 12472171

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 20
Study: 9498512

Group type: EXPERIMENTAL
Intervention: 600 IU/kg intravenous EPO three times weekly
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 19
Study: 7611589

Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms, four times a day)
Number of subjects: 8843

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8843

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 8843
Study: 1978371

Group type: EXPERIMENTAL
Intervention: Ipsapirone 15 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipsapirone 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 389346

Group type: EXPERIMENTAL
Intervention: Anal dilatation
Number of subjects: 216

Group type: COMPARATOR
Intervention: Sphincterotomy
Number of subjects: 216

Group type: COMPARATOR
Intervention: High-fibre diet
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Rubber-band ligation
Number of subjects: 216

Group type: COMPARATOR
Intervention: Cryosurgery
Number of subjects: 216

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 216
Study: 30448183

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 29178943

Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF) at a dose of 70 ml/kg/hour for 48 hours
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (standard management)
Number of subjects: 28
Study: 25923551

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including audits of indications for cesarean delivery, feedback to health professionals, and implementation of best practices.
Number of subjects: 184952

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 184952

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 184952
Study: 23619733

Group type: EXPERIMENTAL
Intervention: Revision TKA in patients with BMI < 30 kg/m2
Number of subjects: 75

Group type: COMPARATOR
Intervention: Revision TKA in patients with BMI ≥ 30 kg/m2
Number of subjects: 75
Study: 22168642

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 86
Study: 19134020

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (Bifidobacterium longum (BL999) 1 x 10(7) CFU/g and Lactobacillus rhamnosus (LPR) 2 x 10(7) CFU/g)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 253
Study: 17343738

Group type: EXPERIMENTAL
Intervention: Specialist heart failure nurse care plus a nurse-led predominantly home-based exercise intervention
Number of subjects: 169

Group type: COMPARATOR
Intervention: Specialist heart failure nurse care alone
Number of subjects: 169
Study: 15083363

Group type: EXPERIMENTAL
Intervention: High altitude exposure (15-20 days at 5,050 m)
Number of subjects: 12
Study: 11642024

Group type: EXPERIMENTAL
Intervention: Vancomycin (23 F per gram) in continuous infusion through a central venous catheter
Number of subjects: 30

Group type: COMPARATOR
Intervention: Teicoplanin (311‐357 F a 400 mg vial) intramuscularly
Number of subjects: 30
Study: 9527806

Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 0
Study: 8050692

Group type: EXPERIMENTAL
Intervention: Heating of CO2 gas to 37 degrees C during insufflation
Number of subjects: 0
Study: 3058475

Group type: EXPERIMENTAL
Intervention: Propofol 1‐1.5 mg kg‐1 body weight
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Methohexitone 0.75‐1 mg kg‐1 body weight
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both agents
Number of subjects: 30
Study: 29349919

Group type: EXPERIMENTAL
Intervention: Phone calls to schedule next consultation a week in advance (Group A)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Scheduling next appointment at the end of each visit (Group B)
Number of subjects: 116
Study: 27639100

Group type: EXPERIMENTAL
Intervention: Higher concentrations of urinary free cortisol (UFC), DHEAs, IGF‐I and lower free T4 in women
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Higher urinary free cortisol (UFC) concentration in women
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Higher testosterone in men
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Higher IGF‐I concentration in men
Number of subjects: 383

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 383
Study: 24253484

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 60 mg daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 34
Study: 23860961

Group type: EXPERIMENTAL
Intervention: Alprostadil (0.4 μg/kg/day) in 100 ml sterile saline
Number of subjects: 370

Group type: COMPARATOR
Intervention: Sterile saline (control group)
Number of subjects: 370
Study: 19243750

Group type: EXPERIMENTAL
Intervention: 200 mug of misoprostol (n = 25)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (n = 27)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 200 mug of misoprostol (n = 13, subgroup 1)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (n = 12, subgroup 1)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 200 mug of misoprostol (n = 15, subgroup 2)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (n = 12, subgroup 2)
Number of subjects: 52
Study: 18835071

Group type: EXPERIMENTAL
Intervention: Chronic trapezius myalgia
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 62
Study: 16623075

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ 150/12.5 mg (8 weeks)
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ 300/25 mg (8 weeks)
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ treatment
Number of subjects: 825
Study: 12794569

Group type: EXPERIMENTAL
Intervention: Biofeedback with anal manometry
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Biofeedback with transanal ultrasound
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pelvic floor exercises with feedback from digital examination alone
Number of subjects: 120
Study: 11336155

Group type: EXPERIMENTAL
Intervention: Jejunal meal feeding (liquid meal at 2 kcal/2 ml/min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 15
Study: 9180659

Group type: EXPERIMENTAL
Intervention: Restraint education with consultation (REC)
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Restraint education (RE)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 643
Study: 8204290

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg b.d. for 8 days (25 patients)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Amoxycillin/clavulanate 500 mg t.d.s for 8 days (22 patients)
Number of subjects: 47
Study: 3110441

Group type: EXPERIMENTAL
Intervention: Single lumen catheter (SLC)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Triple lumen catheter (TLC)
Number of subjects: 75
Study: 31999174

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 853

Group type: COMPARATOR
Intervention: Control
Number of subjects: 853
Study: 29064872

Group type: EXPERIMENTAL
Intervention: Albumin 5%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Balanced hydroxyethyl starch 6% (130/0.4)
Number of subjects: 100
Study: 28914359

Group type: EXPERIMENTAL
Intervention: Normoxia
Number of subjects: 19

Group type: COMPARATOR
Intervention: Hypoxia
Number of subjects: 19
Study: 25532076

Group type: EXPERIMENTAL
Intervention: Cariprazine 3-12 mg/day
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study: 22913568

Group type: EXPERIMENTAL
Intervention: LACA using the Arctic Front® catheter
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: LACA using the HD Mesh Ablator® catheter
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both interventions (Arctic Front® and HD Mesh Ablator®)
Number of subjects: 37
Study: 21427078

Group type: EXPERIMENTAL
Intervention: C24T variant allele in MRP2 under macrolides treatment (Tacrolimus and Sirolimus)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: C24T variant allele in MRP2 under cyclosporine treatment
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: C3972T variant allele in MRP2
Number of subjects: 66
Study: 18308218

Group type: COMPARATOR
Intervention: Acetaminophen plus ibuprofen (AcIBU)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Acetaminophen plus codeine plus caffeine (Tylenol No. 3)
Number of subjects: 146
Study: 16681972

Group type: EXPERIMENTAL
Intervention: Single stapler combined with prolapsing technique
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional double stapler technique
Number of subjects: 43
Study: 14498816

Group type: EXPERIMENTAL
Intervention: Positive musical mood induction
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Negative musical mood induction
Number of subjects: 109

Group type: COMPARATOR
Intervention: No-music control condition
Number of subjects: 109
Study: 10875715

Group type: EXPERIMENTAL
Intervention: Morphine 0.15 mg x kg(‐1) (R/M15 group)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Morphine 0.20 mg x kg(‐1) (R/M20 group)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Fentanyl (F group)
Number of subjects: 210
Study: 9106381

Group type: EXPERIMENTAL
Intervention: Assisted bath
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control day (no bath)
Number of subjects: 10
Study: 29498350

Group type: EXPERIMENTAL
Intervention: Moderate vitamin D3 supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Higher vitamin D intake
Number of subjects: 0
Study: 27142170

Group type: EXPERIMENTAL
Intervention: Irinotecan plus S-1 (IRI-S)
Number of subjects: 126

Group type: COMPARATOR
Intervention: S-1
Number of subjects: 126